Splanchnic Vein Thrombosis: Current Perspectives

Abstract: Splanchnic vein thrombosis (SVT) including portal, mesenteric, splenic vein thrombosis and the Budd-Chiari syndrome, is a manifestation of unusual site venous thromboembolism. SVT presents with a lower incidence than deep vein thrombosis of the lower limbs and pulmonary embolism, with portal vein thrombosis and Budd-Chiari syndrome being respectively the most and the least common presentations of SVT. SVT is classified as provoked if secondary to a local or systemic risk factor, or unprovoked if the causative trigger cannot be identified. Diagnostic evaluation is often affected by the lack of specificity of clinical manifestations: the presence of one or more risk factors in a patient with a high clinical suspicion may suggest the execution of diagnostic tests. Doppler ultrasonography represents the first line diagnostic tool because of its accuracy and wide availability. Further investigations, such as computed tomography and magnetic resonance angiography, should be executed in case of suspected thrombosis of the mesenteric veins, suspicion of SVT-related complications, or to complete information after Doppler ultrasonography. Once SVT diagnosis is established, a careful patient evaluation should be performed in order to assess the risks and benefits of the anticoagulant therapy and to drive the optimal treatment intensity. Due to the low quality and large heterogeneity of published data, guidance documents and expert opinion could direct therapeutic decision, suggesting which patients to treat, which anticoagulant to use and the duration of treatment.

Keywords: Budd-Chiari syndrome, mesenteric vein thrombosis, portal vein thrombosis, splanchnic vein thrombosis, splenic vein thrombosis

Introduction
Splanchnic vein thrombosis (SVT) refers to thrombosis occurring in the splanchnic venous circulation, which drains the digestive system from the lower oesophagus to the upper two-thirds of the rectum. SVT encompasses portal vein thrombosis (PVT), mesenteric veins thrombosis (MVT), splenic vein thrombosis and the Budd-Chiari syndrome (BCS). The BCS includes any obstruction of the hepatic venous outflow located between the small hepatic venules and the confluence of the inferior vena cava into the right atrium. Thrombosis of the extrahepatic portal axis with possible extension to other splanchnic veins is sometimes referred under the term extrahepatic portal vein obstruction (EHPVO), although EHPVO can also include other mechanisms of portal vein obstruction (e.g. neoplastic infiltration).

Epidemiology
SVT is an unusual manifestation of venous thromboembolism (VTE). While usual site VTE, i.e. deep vein thrombosis of the lower limbs and pulmonary embolism, occur in about 70–270 cases per 100,000 person-years, the incidence of SVT is at least 25 times lower. Furthermore, a high variability in the incidence of SVT has
been reported which may depend on the type of data source, differences in diagnostic tests, site or type of SVT - incidental or symptomatic - considered.

PVT is the most frequent type of SVT. A prevalence of 1.0% was reported in a large population study evaluating more than 23,000 consecutive autopsies, while an incidence of 3.7 cases per 100,000 person-years was reported in a large multicentre Swedish study.

BCS is the least common manifestation of SVT, with reported incidence rates of around 1–2 cases per million inhabitants per year. The estimated prevalence of BCS varies across different countries, ranging from around 1–4 cases per million inhabitants in the West to 5–7 cases per million inhabitants in the East.

Age and sex distribution of SVT is heterogeneous, with some differences based on the site of thrombosis. Patients with BCS tend to be the youngest especially in Asian countries, where incidence peaks between 20 and 40 years. Although this difference is less pronounced in Western countries, BCS patients are still approximately one decade younger than PVT patients (for instance 50 vs 61 years, or 45 vs 54 years, respectively, in the Italian and US cohorts). Conversely, the incidence of MVT is higher around 70–79 years.

Approximately two thirds of SVT patients are men. Recent data from hospital admissions in North-western Italy documented an annual incidence of PVT of 3.78 and 1.73 cases per 100,000 inhabitants in men and women, respectively. BCS showed a predominance of women (52-69%) in Western studies, whereas a slight predominance of men was reported in Asian studies.

This finding can reflect the different pathogenesis of BCS, being hormonal factors more frequent in the West and membranous web obstruction in the East.

**Risk Factors**

Identification of the causative trigger allows the classification of SVT as provoked or unprovoked, based on the presence or absence of a local or systemic risk factor (Table 1). The variable prevalence of risk factors among patients with SVT may be explained by differences in study populations. In unselected cohorts of SVT patients, the major risk factors are liver cirrhosis and solid cancer, each responsible for about 25% of cases, while unprovoked SVT represents 15% to 27% of all SVTs.

Cirrhotic patients present both a pro-coagulant status and portal axis hemodynamic alterations which may favour the occurrence of SVT. Recent data showed that patients with liver cirrhosis are not naturally “anticoagulated” as previously believed, and may be at increased risk of thrombosis due to an acquired pro-thrombotic status related to high factor VII/protein C ratio, increased thrombin generation, and alteration in fibrin clot structure. Additionally, reduced portal flow can contribute to PVT development. Results of clinical studies confirmed these experimental data showing an increased VTE risk and a prevalence of PVT of about 10% in cirrhotic patients.

The association between solid cancer and VTE can be explained by cancer-related haemostatic system alterations and other risk factors frequently associated with cancer, such as immobilization, surgery, chemotherapy, and central venous catheter. The prevalence of cancer-related SVT is low in outpatients (about 1%), with liver (26%) and pancreatic (11%) cancers being the most common neoplasms. Furthermore, 15% of patients with SVT receive a diagnosis of solid cancer after a median follow-up of 1.6 years, suggesting that, as usual sites VTE, SVT may be an early marker of cancer.

| Risk Factors For Splanchnic Vein Thrombosis |
|---------------------------------------------|
| **Risk Factors For Splanchnic Vein Thrombosis** |
| **Persistent Acquired Risk Factors** | **Transient Acquired Risk Factors** | **Inherited Risk Factors** |
| Liver cirrhosis | Intra-abdominal Inflammations/infections | Factor V Leiden mutation |
| Solid cancer | Abdominal surgery | Prothrombin G20210A mutation |
| Myeloproliferative neoplasm | Hormonal therapy | JAK2V617F mutation |
| Inflammatory bowel disease | Pregnancy or puerperium | Protein C deficiency |
| Anti phospholipid syndrome | | Protein S deficiency |
| Other hematologic disease (e.g. PNH) | | Antithrombin deficiency |
| Autoimmune disease (e.g. Behçet’s disease) | | |

**Abbreviations:** PNH, paroxysmal nocturnal haemoglobinuria; SVT, splanchnic vein thrombosis.
Patients with myeloproliferative neoplasms (MPN) show an increased risk for both arterial and venous thrombosis. The incidence of SVT is higher in MPN (from 1% to about 20%) than in the general population, and about 10% of all SVT are MPN-related. The pathogenesis of thrombosis in MPN is a complex and multifactorial process involving quantitative and qualitative alterations of platelet, erythrocytes, leukocytes, and endothelial cells. The V617F substitution of the Janus Kinase 2 (JAK2) gene showed a strong association with MPN and SVT. The prevalence of JAK2V617F mutation is higher in SVT (32.7%) compared with usual sites VTE (0.88%), cerebral vein thrombosis (2.57%) or retinal vein occlusion (0.99%). Furthermore, this mutation was found in 94.7% of patients with unusual site thrombosis (cerebral and SVT) and overt MPN. From a pathophysiological point of view, the JAK2V617F mutation seems to promote thrombosis through P-selectin overexpression leading to platelet aggregation and fibrin deposition.

Hormonal therapy, abdominal surgery (e.g. splenectomy, liver transplantation and bariatric surgery), inflammatory bowel diseases (Crohn’s disease and ulcerative colitis), pregnancy or puerperium are responsible for the majority of the remaining cases of SVT. Furthermore, intra-abdominal infections (e.g. diverticulitis, appendicitis, pancreatitis) due to anaerobes, aerobic bacteria or fungi may cause pylephlebitis. Other rare causes of SVT are paroxysmal nocturnal hemoglobinuria and Behçet’s disease.

Thrombophilia may be an additional risk factor, although low levels of anticoagulant proteins are generally related to an impaired liver production. The prevalence of significant thrombophilia (mainly factor V Leiden, prothrombin G20210A, and JAK2V617F mutations) is higher in SVT (12.3%) than usual site VTE (8.5%). In particular, BCS, MVT and multiple veins thrombosis show the highest rate of pro-thrombotic alterations. Finally, one third of patients with SVT present with more than one risk factor, reflecting the multifactorial aetiology of SVT.

Specific venous involvement in SVT shows some peculiarities based on the associated risk factors. While about 90% of cirrhosis-related SVT involve the portal vein, cancer-related SVT involves the portal, splenic, and superior mesenteric veins in 48%, 42%, and 21% of cases, respectively. In patients with MPN, PVT is the most common type of SVT (about 60%); however, the prevalence of BCS is higher in MPN patients (approximately 17% of MPN-related SVT are BCS, while <10% of BCS were reported among all SVT). Nearly half of patients with pancreatitis show splenic vein involvement. Multiple vessels thrombosis is reported in approximately a fifth of patients with cancer (24%), cirrhosis (22%), and MPN (17%).

Clinical Presentation
Clinical manifestations of SVT are nonspecific. The most common symptom is abdominal pain, reported in approximately half of SVT patients, followed by gastrointestinal bleeding and ascites. Other nonspecific symptoms are nausea, vomiting, anorexia, diarrhoea or constipation, and fever. In up to one third of patients, SVT can be asymptomatic or incidentally detected during abdominal imaging performed for other reasons, such as follow-up of cancer or cirrhosis. However, each site of thrombosis can manifest with a specific clinical scenario.

Portal Vein Thrombosis
PVT can be acute or chronic. Acute PVT is characterised by the sudden onset of abdominal pain, whereas signs of portal hypertension (such as hypersplenism, ascites, oesophageal varices, and the presence of portal cavernoma or other porto-systemic collateral veins on imaging) are typical manifestations of chronic PVT.

Mesenteric Vein Thrombosis
MVT can present an acute, subacute or chronic course. Acute MVT is characterised by the sudden onset of abdominal pain and is complicated by intestinal infarction in one third of patients. Abdominal pain lasting for several days without intestinal infarction is more typical of subacute MVT, while signs of portal hypertension identify chronic MVT. MVT has a 30-day mortality rate of 20%, mainly due to bowel infarction.

Splenic Vein Thrombosis
Data on isolated splenic vein thrombosis are scarce. The most common symptom is abdominal pain, reported in 57% of patients, followed by gastrointestinal bleeding (29%) and nausea (23%). Up to 17% of patients can be asymptomatic.

Budd-Chiari Syndrome
BCS can be fulminant, acute, subacute or chronic. Patients with BCS typically present with a triad of abdominal pain, ascites, and hepatomegaly. In fulminant BCS, the rapid onset of hepatocellular necrosis may lead to
acute liver failure within few days, while chronic BCS generally presents with signs of portal hypertension.55

**Diagnosis**

The diagnosis of SVT relies on imaging. D-dimer, a well-known biomarker for deep vein thrombosis and pulmonary embolism, has limited utility in this setting. Although some studies showed that mean D-dimer values are increased in SVT patients,56,57 D-dimer can also be elevated in other conditions, such as liver cirrhosis or hepatocellular carcinoma, which reduces its diagnostic predictive value.58 Recent data suggested that D-dimer levels may predict the development of multi-organ dysfunction and short-bowel syndrome after acute MVT.59

Angiography was the gold standard for SVT diagnosis, but it is an invasive examination and rarely performed nowadays. Doppler ultrasonography (DUS) has become the first line diagnostic test with a sensitivity of 89-93% and a specificity of 92-99% for PVT.60 DUS is also very accurate for BCS since it can directly visualise the intra- and supra-hepatic veins and the inferior vena cava, the typical intrahepatic collaterals, and the texture of the liver parenchyma.61 The sensitivity of DUS is lower for the mesenteric veins, due to the bowel gas which can interfere with their visualisation,62 and for the splenic vein, due to the presence of several collaterals near the splenic hilum.63

Computed tomography (CT) angiography and magnetic resonance (MR) angiography are nowadays the standard imaging for MVT, since they can better visualise the mesenteric veins and show signs of intestinal infarction.54 They can also be used in patients with suspected PVT or BCS, when the DUS is not diagnostic or to complete information from DUS.65 CT angiography is faster and widely available, but involves ionizing radiations and the iodinated contrast agent can cause allergic reactions or renal toxicity. MR angiography is used for patients with contraindications to CT angiography, since the scanning time is longer (30–60 mins) and has lower spatial resolution.60 Liver biopsy is usually not needed, except to confirm rare forms of BCS involving only the small intrahepatic veins or to exclude other hepatic disorders, such as the veno-occlusive disease.65,66

Distinguishing acute or recent PVT from chronic PVT represents a difficult but relevant challenge with therapeutic implications. Acute PVT is visualised as hyperechoic material into an enlarged vein with partial or total absence of vascular flow on DUS or as hyperattenuating material without luminal contrast enhancement on CT. Portal cavernoma, easily detected by both DUS and CT, is the main sign of chronic thrombosis and is defined as the presence of multiple small collaterals around the PVT.67,68 In doubtful cases, the clinical presentation, the absence of collateral circulation, and the absence of SVT in previous exams could help establishing the diagnosis of acute/recent SVT.58

**Treatment**

During the last few years, a large number of observational studies tried to evaluate the safety and efficacy of anticoagulant treatment in patients with SVT. The paucity and variability of available data in terms of type, dose, and duration of anticoagulant therapy can be explained by the relative rarity, extreme clinical variability, and challenging diagnostic evaluation of SVT. All these aspects may have contributed to the heterogenous level of evidence and grade of recommendations in published guidelines.2,3,69–71 Furthermore, “real world” patients are often more complex compared to the typical cases considered by the guidelines and require a careful evaluation of the risk-to-benefit balance of the anticoagulant treatment.

**Pre-Treatment Evaluation**

Before starting anticoagulant treatment, physicians need to carefully evaluate the bleeding risk which is mainly related to portal hypertension complications, such as ascites, varices, or gastro-intestinal bleeding at clinical presentation.68,72,73 The presence of oesophageal varices is an independent risk factor for major bleeding,72,73 thus an upper endoscopy to grade and eventually treat oesophageal varices should be considered before starting the anticoagulant therapy, especially in patients with liver cirrhosis and chronic SVT.21,68 The presence of oesophageal varices should not necessarily contraindicate or defer anticoagulant therapy which can improve the portal hypertension, as long as appropriate prophylactic measures are taken (beta-blockers or endoscopic treatment).69 However, since endoscopic band ligation can require multiple sessions, in patients without active bleeding, an initial treatment with reduced or prophylactic doses of low molecular weight heparin (LMWH) could be considered.74

**Who Should Be Treated?**

Treatment of acute SVT aims to achieve vessel recanalization and avoid complications, such as bowel ischemia or chronic portal hypertension.67 Therefore, starting anticoagulant therapy in acute symptomatic SVT without absolute
contraindications is strongly recommended.\textsuperscript{2,3,69} Prevention of thrombosis progression or recurrence is the main goal of anticoagulant therapy in patients with chronic SVT, especially those with persistent risk factors. However, several areas of uncertainty still exist in the treatment of chronic SVT.\textsuperscript{67,75}

The 9\textsuperscript{th} edition of the American College of Chest Physician (ACCP) guidelines strongly recommend anticoagulant therapy in symptomatic patients. Conversely, no treatment is suggested for incidentally detected SVT, possible exceptions being acute and extensive SVT, progression of previous known thrombosis, and ongoing chemotherapy in cancer patients.\textsuperscript{69} Additional information on incidental SVT derived from the results of two recent large cohort studies. In the International Registry on SVT (IRSVT), the prognosis of incidentally detected SVT was comparable to symptomatic SVT,\textsuperscript{19,51} similarly to previous data on VTE at usual sites.\textsuperscript{76} Although the use of anticoagulant treatment was significantly lower in patients with incidentally detected SVT (64%) compared with symptomatic patients (84%), the incidence of thrombotic events was not negligible. An overall incidence rate of thrombotic events 8.0 (95% CI, 5.2–12.1) and 7.0 (95% CI, 5.2–9.3) per 100 person-year was reported in incidentally detected and symptomatic SVT, respectively. In particular, untreated incidental SVT had an incidence rate of 11.5 events (95% CI, 6.2 to 21.3).\textsuperscript{51} Similar results came from the “Registro Informatizado Enfermedad Trombo Embólica” (RIETE) registry where patients with incidentally detected SVT presented a non-significantly higher rate of symptomatic recurrent VTE than those with symptomatic SVT.\textsuperscript{52}

**Anticoagulant Choice**

Several studies showed that early start of anticoagulation therapy (within one-two weeks from diagnosis) promotes better vessel recanalization compared to commencing later.\textsuperscript{77–79} Only one recent study found no correlation between early anticoagulant therapy and thrombosis recanalization possibly due to the use of vitamin K antagonists (VKA) without concomitant LMWH administration while reaching the target international normalised ratio (INR).\textsuperscript{80}

LMWH and VKA are the mainstay of the anticoagulant treatment for SVT (Table 2).\textsuperscript{2,3,69–71} Treatment is usually commenced with LMWH switching to VKA after a few days of overlapping treatment, once the INR is in the target range (2.0–3.0).\textsuperscript{69} However, continuation of LMWH alone may be preferred in cases of low platelet count, active cancer, or hepatic disease.\textsuperscript{69}

To date, only few but promising data are available on the direct oral anticoagulants (DOAC) for the treatment of SVT. In a recent small randomized controlled trial in 80 cirrhotic patients with PVT, rivaroxaban seemed more effective and safer compared with VKA.\textsuperscript{81} In a retrospective cohort of 50 cirrhotic patients with PVT treated with edoxaban or warfarin after an initial 2-week period with danaparoid sodium, edoxaban reduced recurrent VTE but increased the rate of major bleeding compared with VKA dose-adjusted to a lower INR target range (1.5–2.0).\textsuperscript{82} Finally, a small prospective observational cohort of patients with atypical site thrombosis including 26 SVTs, found similar rates of VTE recurrence and bleeding in patients treated with apixaban or rivaroxaban and those on enoxaparin.\textsuperscript{83} While waiting for future data, clinicians should cautiously consider the use of DOACs for SVT, as they are still considered off-label in this group of patients. The same therapeutic schemes and dose modification as for usual site VTE could be applied with a careful clinical and laboratory follow-up.\textsuperscript{74}

However, all DOACs are contraindicated in patients with Child-Pugh class C, and rivaroxaban is contraindicated also in Child-Pugh class B. A number of ongoing studies is evaluating the use of the DOAC in SVT patients (NCT02627053, NCT02555111, NCT03193502, NCT03778502).

Concomitant medications and patient comorbidities (e.g. low platelet count, chronic liver disease, and moderate to severe renal failure) need to be carefully considered when deciding on the type and dose of anticoagulant treatment.\textsuperscript{2,69,84–88} Based on current available evidence on the treatment of patients with usual site VTE and expert opinions, our suggested approach to SVT patients with the above mentioned comorbidities is summarised in Table 3.\textsuperscript{21,84,85,89–93}

**For How Long Should Patients Be Treated?**

The recommended duration of anticoagulant therapy differs across guidelines (Table 2). The ACCP guidelines suggest 3 months of anticoagulant treatment in patients with a transient thrombotic risk factor and longer duration in those with a persistent thrombotic risk factor or unprovoked SVT and low bleeding risk.\textsuperscript{69}
# Table 2 Guidelines Recommendations For The Anticoagulant Treatment Of Splanchnic Vein Thrombosis

**AASLD 2009**

| Type Of Patients | Type Of Anticoagulation | Duration Of Anticoagulation |
|------------------|-------------------------|-----------------------------|
| **EHPVO**        |                         |                             |
| Acute            | LMWH → VKA (I,B)        | Transient risk factor       |
|                  |                         | Persistent risk factor      |
| Chronic          | Not specified           | Transient risk factor       |
|                  |                         | Persistent risk factor      |
| **BCS**          | LMWH → VKA (I,B)        | Permanent anticoagulant     |
| Cirrhotic        | Case by case decision*  |                             |

**AISF 2011**

| Type of patients | Type of anticoagulation | Duration of anticoagulation |
|------------------|-------------------------|-----------------------------|
| **EHPVO**        |                         |                             |
| Acute            | LMWH → VKA              | At least 6 months<sup>6</sup>|
| Chronic          | Not specified           | Not specified<sup>6</sup>   |
| **BCS**          | LMWH → VKA              | Not specified               |

**ACCP 2012**

| Type of patients | Type of anticoagulation | Duration of anticoagulation |
|------------------|-------------------------|-----------------------------|
| **SVT (except BCS)** | Incidentally detected (2, C) | Not suggested*              |
| Symptomatic (1,B) | LMWH → VKA              | Transient risk factor       |
|                  |                         | Persistent risk factor      |
|                  |                         | or unprovoked               |
| **BCS**          | Incidentally detected (2,C) | Not suggested*              |
| Symptomatic (2,C) | LMWH → VKA              | Transient risk factor       |
|                  |                         | Persistent risk factor      |
|                  |                         | or unprovoked               |

**Baveno VI 2015**

| Type of patients | Type of anticoagulation | Duration of anticoagulation |
|------------------|-------------------------|-----------------------------|
| **EHPVO**        | Recent                  | Transient risk factor       |
|                  | LMWH → VKA (2b,B)      | At least 6 months<sup>1</sup> |
|                  |                         | Persistent risk factor      |
| Chronic          | LMWH/VKA               | Transient risk factor       |
|                  |                         | Long-term (3b,B)            |
| **BCS**          | Not specified           | Long-term (5,D)             |
| Cirrhotic        | LMWH/VKA<sup>1</sup>   | Until liver transplantation (4,C) |

<sup>1</sup>no recommendation in non-candidates to liver transplantation<sup>1</sup>
The Baveno VI Consensus Workshop and the European Association for the Study of the Liver recommend at least six months of treatment for acute/recent SVT secondary to transient risk factors and long-term anticoagulation in case of persistent risk factors. Long-term anticoagulation should also be considered in patients with chronic SVT and a persistent pro-thrombotic state and in patients with transient risk factors who have a history of intestinal ischemia or recurrent thrombosis.2,3

Confirming these data, a recent study showed an higher incidence of thrombotic events in patients with unprovoked SVT or SVT related to persistent risk factors such as liver cirrhosis, solid cancer, and MPN.19 Therefore, these categories of patients should be considered for long-term anticoagulation.

In addition, the American Association for the Study of Liver Diseases and the Report of the Baveno VI Consensus Workshop guidelines weakly recommend long-term anticoagulation for patients with thrombus extension into the mesenteric veins.3,71 Finally, long-term anticoagulant therapy should be administered to all patients with BCS, especially if unprovoked.3

Thrombus extension (partial versus total occlusion), involvement of multiple vessels, and lack of recanalization during follow-up are all associated with worse prognosis and should be considered when deciding on treatment duration.21 Indeed, the dose and duration of the anticoagulant therapy was directed by the rate of vessel recanalization in several studies.68,84,95

Our recommendations on the anticoagulant treatment in patients with SVT are summarized in Figure 1.

### Thrombolysis

Only few studies evaluated the role of thrombolysis in SVT and reported conflicting results. Smallberg and colleagues showed that its effectiveness may be associated with a not negligible risk of bleeding.96 In contrast, promising results were reported in another study involving patients with acute MVT.97,98

The use of thrombolysis may be carefully considered in specialized centres for very selected cases (e.g. failure of anticoagulant therapy or MVT complicated by intestinal ischemia).74

### Budd-Chiari Syndrome

Due to the severity of BCS, anticoagulant treatment should be established as soon as possible and continued lifelong. Patients not-responsive to medical treatment should be managed
according to a stepwise approach with angioplasty/stenting or thrombolysis, followed by trans-jugular intrahepatic portosystemic shunting (TIPS) and, at last, orthotopic liver transplantation.\(^2,3\) It has been reported that approximately half of BCS patients require interventional procedures.\(^9,99\)

### Prognosis

Data from several observational studies showed that the prognosis of SVT depends on several variables, such as older age, underlying risk factors (e.g. active cancer and MPN), site and extension of SVT.\(^16,21\) In an international prospective cohort study evaluating the long-term clinical outcomes of 604 patients with SVT, the mortality rate was 10.3 per 100 patient-years (95% CI, 8.5 to 12.5) during a median follow-up of 2 years.\(^19\) The highest and the lowest mortality rates were reported, respectively, in patients with solid cancer (39.5 per 100 patient-years; 95% CI, 31.1 to 50.1) and with unprovoked SVT (2.3 per 100 patient-years; 95% CI, 1.1 to 4.8).\(^19\) Data from Danish registries showed that MVT was associated with the highest 30-day mortality rate (63.1%), followed by PVT and BCS (15.6% and 13.2%, respectively).\(^18\)

Furthermore, SVT carry also an increased risk of bleeding events and arterial cardiovascular events.\(^100\) The risk of bleeding was particularly relevant in the first 30 days (4.3% in SVT patients vs 0.5% in patients with DVT or PE), and remained significantly higher than usual site VTE up to 10 years after SVT diagnosis. The risk of cardiovascular events was also particularly relevant in the first 30 days (3.3% in SVT patients vs 0.9% in patients with DVT or PE), but remained high up to 1 year.\(^100\)

### Table 3

| Comorbidity          | Anticoagulant Therapy |
|----------------------|-----------------------|
| **Thrombocytopenia** |                       |
| PLT 50-149,000/μl   | Therapeutic dose       |
| PLT 25-<50,000/μl   | 50% of therapeutic dose or prophylactic dose*** |
| PLT < 25,000/μl     | Discontinue temporarily |
| **Kidney failure**  |                       |
| GFR 30–50 mL/min    | Therapeutic dose       |
| GFR 15–<30 mL/min   | 50% of therapeutic dose** |
| GFR <15 mL/min      | Not recommended        |
| **Liver cirrhosis** |                       |
| Child-Pugh A        | Therapeutic dose       |
| Child-Pugh B        | Therapeutic dose       |
| Child-Pugh C        | Not recommended        |

Notes: \(^*\)In several countries the DOACs are currently not licensed for the treatment of SVT patients.\(^99\)\(^*\)Limited experience is available in patients with platelet count <100,000/μl, consider switching to LMWH or VKA.\(^**\)In patients with acute thrombosis and high risk of thrombus progression, consider therapeutic LMWH dose and platelet transfusion support to maintain a platelet count of ≥ 40–50,000/μl.\(^*\)Consider monitoring the anti-factor Xa activity (target range 0.6–1.0 U/mL for enoxaparin BID, >1.0 U/mL for enoxaparin OD) or switching to UFH. Enoxaparin is the most studied LMWH in patients with kidney failure.\(^*\)Patients with chronic kidney disease (low GFR values) might require lower doses to maintain the INR within the therapeutic range.\(^*\)Since INR might not reflect the anticoagulation status, caution should be used in patients with Child-Pugh C class.\(^**\)Use with caution if liver enzymes > 2 ULN.

Abbreviations: A, apixaban; BID, twice daily; D, dabigatran; DOAC, direct oral anticoagulant; E, edoxaban, GFR, glomerular filtration rate; INR, international normalized ratio; LMWH, low molecular weight heparin; OD, once daily; PLT, platelet count; R, rivaroxaban; UFH, unfractionated heparin; ULN, upper limit of normal; VKA, vitamin K antagonist.
Conclusions

SVT represents a diagnostic and therapeutic challenge. Based on limited available evidence, treatment decisions should be individualized with careful evaluation of the risks of bleeding and SVT recurrence or extension. The presence of oesophageal varices does not represent an absolute contraindication for anticoagulant therapy, but medical and endoscopic prophylaxis are warranted before starting anticoagulation to reduce bleeding risk. LMWH and VKA are the treatment of choice for SVT whereas the use of DOACs remains still off-label in several countries. Recent evidence suggests that incidentally detected SVT has similar prognosis as symptomatic SVT and a similar treatment approach is suggested. Treatment of chronic SVT is still controversial, especially in cirrhotic patients, but it should be considered in patients with persistent risk factors or selected cases at high risk of progression. Similarly to usual site VTE, a short course of anticoagulation (up to 6 months) is suggested for SVT provoked by transient risk factors, whereas longer treatment duration should be considered for unprovoked SVT, SVT provoked by persistent risk factors, and SVT with a high risk of recurrence or progression.

A great scientific effort has been made in the past years trying to clarify some of the challenges associated with SVT. However, future studies will be needed to strengthen some areas of uncertainty including both the diagnostic (e.g. identification of new underlying diagnostic and prognostic risk factors) and therapeutic approaches (e.g. identification of which patients to treat, which anticoagulant to use and the duration of treatment) to SVT.

Disclosure

EV and NR report no conflicts of interest in relation to this paper. MDN reports personal fees from Bayer, Daiichi Sankyo, Pfizer, Leo Pharma, and Aspen, outside the submitted work. WA has received a research grant from Bayer to support a clinical study in patients with splanchnic vein thrombosis, received honoraria for participation at advisory boards from Bayer, Boehringer Inghelheim, Daiichi Sankyo, BMS/Pfizer, Sanofi, and Portola, and reports
grants and personal fees from Bayer, and personal fees from BMS/Pfizer, Daiichi Sankyo, Sanofi, Aspen, and Portola, outside the submitted work. The authors report no other conflicts of interest in this work.

References

1. Myers K, Hannah P. Anatomy of veins and lymphatics. In: Myers K, Hannah P, editors. Manual of Venous and Lymphatic Diseases. London, UK: Taylor & Francis Ltd. 2018:13–38.

2. European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J hepatol. 2016;64(1):179–202. doi:10.1016/j.jhep.2015.07.040

3. de Franchis R, Faculty BV. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–752. doi:10.1016/j.jhep.2015.05.022

4. Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340–1347. doi:10.1161/CIRCRESAHA.115.306841

5. Ageno W, Squizzato A, Togni A, et al. Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. J Thromb Haemost. 2012;10(1):158–160. doi:10.1111/j.1538-7836.2011.04565.x

6. Ögren M, Bergqvist D, Björnck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: A population study based on 23 796 consecutive autopsies. World J Gastroenterol. 2006;12(13):2115–2119. doi:10.3748/wjg.v12.i13.2115

7. Rajani R, Björnsson E, Bergquist A, et al. The epidemiology and incidence of Budd-Chiari syndrome: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2018; pii: S2210-7401(18)30230-4. doi: 10.1016/j.clinre.2018.10.014. [Epub ahead of print] PubMed PMID: 30528513.

8. Ageno W, Dentali F, Pomero F, et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. Thromb Haemost. 2017;117(4):794–800. doi:10.1160/TH16-10-0781

9. Rajani R, Melin T, Björnsson E, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience. Liver Int. 2009;29(2):253–259. doi:10.1111/j.1478-7321.2008.01838.x

10. Ollivier-Hourmand I, Allaire M, Goutte N, et al. The epidemiology of Budd-Chiari syndrome in France. Dig Liver Dis. 2018;50(9):931–937. doi:10.1016/j.dld.2018.04.004

11. Ki M, Choi HY, Kim KA, Kim BH, Jang ES, Jeong SH. Incidence, prevalence and complications of Budd-Chiari syndrome in South Korea: a nationwide, population-based study. Liver Int. 2016;36(7):1067–1073. doi:10.1111/liv.13008

12. Zhang W, Qi X, Zhang X, et al. Budd-Chiari Syndrome in China: a systematic analysis of epidemiological features based on the Chinese literature survey. Gastroenterol Res Pract. 2015;2015:738548. doi:10.1155/2015/750932

13. Parkash O, Khan A, Hamid S. Clinical characteristics and outcome of Budd-Chiari Syndrome at a Tertiary Care Hospital in Pakistan. J Coll Physicians Surg Pak. 2017;27(5):301–304. doi:2617

14. Zhang W, Wang QZ, Chen XW, et al. Budd-Chiari syndrome in China: a 30-year retrospective study on survival from a single center. World J Gastroenterol. 2018;24(10):1134–1143. doi:10.3748/wjg.v24.i10.1134

15. Thatpellie MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchic vein thromboses. Clin Gastroenterol Hepatol. 2010;8(2):200–205. doi:10.1016/j.cgh.2009.09.019

16. Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg. 2008;95(10):1245–1251. doi:10.1002/bjs.6319

17. Søgaard KK, Darvalis B, Horváth-Puhi É, Sørensen HT. Survival after splanchic vein thrombosis: a 20-year nationwide cohort study. Thromb Res. 2016;141:1–7. doi:10.1016/j.thromres.2016.02.024

18. Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175(9):1474–1480. doi:10.1001/jamainternmed.2015.3184

19. Derman BA, Kwaan HC. Risk Factors, Diagnosis, Management, and. Outcome of splanchic vein thrombosis: a retrospective analysis. Semin Thromb Hemost. 2015;41(5):503–513.

20. Ageno W, Dentali F, Squizzato A. How I treat splanchic vein thrombosis. Blood. 2014;124(5):3685–3691. doi:10.1182/blood-2014-07-551515

21. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology. 2009;137(6):2105–2111. doi:10.1053/j.gastro.2009.08.045

22. Gatt A, Riddell A, Calvaruso V, Tuddenden EG, Makris K, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost. 2010;8(9):1994–2000. doi:10.1111/j.1538-7836.2010.03937.x

23. Hugenholz GC, Macrae F, Adelmeijer J, et al. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. J Thromb Haemost. 2016;14(5):1054–1066. doi:10.1111/jth.13278

24. Stine JG, Wang J, Shah PM, et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: a matched case-control study. Liver Int. 2018;38(1):94–101. doi:10.1111/liv.13500

25. Ambrosino P, Tarantino L, Di Minno G, et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost. 2017;117(1):139–148. doi:10.1161/TH16-06-0450

26. Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61(2):660–667. doi:10.1002/hep.27546

27. Violi F, Corazza GR, Caldwell SH, et al. Incidence and recurrence of portal vein thrombosis in cirrhotic patients. Thromb Haemost. 2019;113(3):496–499. doi:10.1055/s-0038-1676981

28. Khrona AA. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol. 2009;20(10):1619–1630. doi:10.1093/annonc/mdp068

29. Gerotziafas GT, Galea V, Mbemba E, et al. Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thromb Res. 2012;129(6):779–786. doi:10.1016/j.thromres.2011.07.049

30. Rak J, Milsom C, Magnus N, Yu J. Tissue factor in tumour progression. Best Pract Res Clin Haematol. 2009;22(1):71–83. doi:10.1016/j.beha.2008.12.008

31. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6(6):401–410. doi:10.1016/S1470-2045(05)70207-2

32. Santoro RC, Prejano S, Iannaccaro P. Splanchnic venous thromboembolism in ambulatory cancer patients receiving chemotherapy. XXIII Congress of the International Society on Thrombosis and Haemostasis with the 57th Annual SSC; 2011; Kyoto.
34. Søgaard KK, Farkas DK, Pedersen L, Sørensen HT. Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival. *Blood* 2015;126(8):957–963. doi:10.1182/blood-2015-03-61119

35. Hettiarachchi RJ, Lok J, Prins MH, Büller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. *Cancer*. 1998;83(1):180–185. doi:10.1002/(sici)1097-0142(19980701)83:1<180::aid-cncrev>3.0.co;2-s

36. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. *Blood*. 2013;122(13):2176–2184. doi:10.1182/blood-2013-04-460154

37. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. *Hematol Am Soc Hematol Educ Program*. 2012;571–581. doi:10.1182/asheducation-2012.1.571

38. Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. *Br J Haematol*. 2013;162(6):730–747. doi:10.1111/bjh.12461

39. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase jak2 in human myeloproliferative disorders. *Lancet*. 2005;365(9464):1054–1061. doi:10.1016/S0140-6736(05)67142-9

40. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchic and cerebral venous thrombosis and without overt chronic myeloproliferative disorders. *J Thromb Haemost*. 2007;5(4):708–714.

41. Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for diagnosis of portal vein thrombosis in North America. *Blood*. 2009;113(22):5617–5623. doi:10.1182/blood-2008-12-196014

42. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation markers in myeloproliferative diseases: relationships with JAK2 V617F status, clonality, and antiphospholipid antibodies. *Clin Exp Gastroenterol*. 2011;4(1):289–301. doi:10.1158/0038-2323-IM-12-0661

43. Robertson B, Urquhart C, Ford I, et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V617F status, clonality, and antiphospholipid antibodies. *Blood*. 2009;113(22):5617–5623. doi:10.1182/blood-2008-12-196014

44. Kanellopoulou T, Alexopoulou A, Theodossiades G, Koskinas J, Archimandritis AJ. Pylephlebitis: an overview of non-cirrhotic portal vein thrombosis. *Scand J Infect Dis*. 2007;39(9):591–596. doi:10.1080/03479570600896455

45. Primignani M, Mannauci PM. The role of thrombophilia in cancer patients with portal vein thrombosis. *Nat Clin Pract Gastroenterol Hepatol*. 2009;6(1):37–43. doi:10.1038/ncpgasthep0577

46. Sutkowska E, McBane RD, Tafur AJ, et al. Thrombophilia differences in splanchic vein thrombosis and lower extremity deep vein thrombosis in North America. *J Gastrointest Oncol*. 2013;4(3):1011–1118. doi:10.4103/0973-0043.117536

47. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deoxyribonucleic acid (DNA) test for antiphospholipid antibodies (anti-β2GPI, anti-β2GPI) in patients with portal vein thrombosis. *Liver Int*. 2012;32(6):919–927. doi:10.1111/j.1478-3275.2012.02785.x

48. Keaton C, Aki EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141(2 Suppl):e149S–e496S. doi:10.1378/chest.11-2301
70. Senzolo M, Riggio O, Primignani M. Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis. 2011;43(7):503–514. doi:10.1016/j.dld.2010.11.006

71. DeLeve LD, Valla DC, Garcia-Tsao G, Diseases A. Vascular disorders of the liver. Hepatology. 2009;49(5):1729–1764. doi:10.1002/hep.22772

72. Riva N, Ageno W, Poli D, et al. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. J Thromb Haemost. 2015;13(6):1019–1027. doi:10.1111/jth.12930

73. Spaander MC, Hoekstra J, Hansen BE, Van Buuren HR, Janssen HL. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013;11(3):452–459. doi:10.1111/jth.12121

74. Ageno W, Beyer-Westendorf J, Garcia DA, Lazo-Langner A, McBane RD, Paciaroni M. Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis. 2016;41(1):129–143. doi:10.1007/s11739-015-1308-1

75. Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W. Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res. 2012;130(Suppl 1):S1–S3. doi:10.1016/j.thromres.2012.08.259

76. Di Nisio M, Lee AY, Carrier M, Liebman HA, Khorana AA. Subcommittee on haemostasis and malignancy. Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2015;13(5):880–883. doi:10.1111/jth.12883

77. Turnes J, Garcia-Pagán JC, González M, et al. Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol. 2008;6(12):1412–1417. doi:10.1016/j.cgh.2008.07.031

78. Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Cln Gastroenterol Hepatol. 2012;10(7):776–783. doi:10.1016/j.cgh.2012.01.012

79. Joh JH, Kim DI. Mesenteric and portal vein thrombosis: treated with early initiation of anticoagulation. Eur J Vasc Endovasc Surg. 2005;29(2):204–208. doi:10.1016/j.ejvs.2004.10.005

80. Chen H, Liu L, Qi X, et al. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2016;28(1):82–89. doi:10.1097/MEG.0000000000000482

81. Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vasc Pharmacol. 2019;113:86–91. doi:10.1016/j.vph.2018.05.002

82. Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following dana-paroid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48(1):51–58. doi:10.1111/hepr.12895

83. Jancezak DT, Mimier MK, McBane RD, et al. Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location. Mayo Clin Proc. 2018;93(1):40–47. doi:10.1016/j.mayocp.2017.10.007

84. Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(6):1246–1249. doi:10.1111/jth.14015

85. Grand’Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiol Drugs. 2005;5(5):291–305. doi:10.2165/00129784-200505050-00002

86. Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393. doi:10.1093/eurheartj/ehy136

87. Dhar A, Mullish BH, Thrusr MR. Anticoagulation in chronic liver disease. J Hepatol. 2017;66(6):1313–1326. doi:10.1016/j.jhep.2017.01.006

88. Hughes S, Szeki I, Nash MJ, Thachil J. Anticoagulation in chronic kidney disease patients:the practical aspects. Clin Kidney J. 2014;7(5):442–449. doi:10.1037/jckfho80

89. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e24S–e43S. doi:10.1378/chest.11-2291

90. European Medicines Agency. Eliquis (apixaban): summary of product characteristics. Available from: https://www.ema.europa.eu/documents/product-information/eliquis-epar-product-information_en.pdf (Accessed June 6, 2019).

91. European Medicines Agency. Xiglatro (rivaroxaban): summary of product characteristics. Available from: https://www.ema.europa.eu/documents/product-information/xiglatro-epar-product-information_en.pdf (Accessed June 6, 2019).

92. European Medicines Agency. Pradaxa (dabigatran etexilate): summary of product characteristics. Available from: https://www.ema.europa.eu/documents/product-information/pradaxa-epar-product-information_en.pdf (Accessed June 6, 2019).

93. European Medicines Agency. Xarelto (rivaroxaban): summary of product characteristics. Available from: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf (Accessed June 6, 2019).

94. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology. 2000;32(3):466–470. doi:10.1053/jhep.2000.16597

95. Amitrano L, Guardascione MA, Scaglione M, et al. Splanchnic vein thrombosis and variceal rebledging in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2012;24(12):1381–1385. doi:10.1097/MEG.0b013e328357d5d4

96. Smallberg JH, Spaander MV, Jie KS, et al. Risks and benefits of transcatheter thrombolytic therapy in patients with splanchic venous thrombosis. Thromb Haemost. 2008;100(6):1084–1088.

97. Yang SF, Liu BC, Ding WW, He CS, Wu XJ, Li JS. Initial transcatheter thrombolysis for acute superior mesenteric venous thrombosis. World J Gastroenterol. 2014;20(18):5483–5492. doi:10.3748/wjg.v20.i18.5483

98. Yang S, Zhang L, Liu K, et al. Postoperative catheter-directed thrombolysis versus systemic anticoagulation for acute superior mesenteric venous thrombosis. Ann Vasc Surg. 2016;35:88–97. doi:10.1016/j.avsg.2016.02.019

99. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al.; EN-Vie (European Network for Vascular Disorders of the Liver). Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151(3):167–175. doi:10.7326/0003-4819-151-3-200908040-00004

100. Sogaard KJ, Adelborg K, Darvalics B, et al. Risk of bleeding and arterial cardiovascular events in patients with splanchic vein thrombosis in Denmark: a population-based cohort study. Lancet Haematol. 2018;5(10):e441–e449. doi:10.1016/S2352-3026(18)30133-9
